Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
43.91
+0.17 (+0.39%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
33
34
Next >
Sanofi Stock Is Trading Higher Today - Here's Why
June 20, 2023
Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to...
Via
Benzinga
3 Undervalued Consumer Stocks to Buy in June
June 20, 2023
These undervalued consumer stocks to buy could attract investor attention as possible hedges against inflation and a recession.
Via
InvestorPlace
3 Gene Testing Stocks to Buy Before They Take Off
June 17, 2023
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry.
Via
InvestorPlace
UK Gives Nod To Roomba Maker IRobot-Amazon Deal, Micron Plans To Invest In China Despite Restrictions, Baidu Secures Regulatory Nod for Self-Driving Taxi: Today's Top Stories
June 16, 2023
Benzinga
Via
Benzinga
2 Top Healthcare Stocks to Buy Right Now
June 16, 2023
The demand for healthcare sector goods and services is both predictable and growing.
Via
The Motley Fool
Peering Into GSK's Recent Short Interest
May 19, 2023
Via
Benzinga
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
June 16, 2023
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that
Via
Benzinga
FDA Pushes Review Time For GSK's Blood Cancer Therapy Added Via Sierra Oncology Acquisition
June 16, 2023
The FDA has extended the review period for GSK plc's (NYSE:
Via
Benzinga
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories
June 07, 2023
Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out
Via
Benzinga
GSK's Arexvy Gets the Green Light in Europe: First-Ever RSV Vaccine in Europe for Older Adults
June 07, 2023
The European Commission has approved GSK plc's (NYSE:
Via
Benzinga
June 2023 Stock Considerations
June 07, 2023
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases.
Via
Talk Markets
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
June 06, 2023
Benzinga
Via
Benzinga
FDA Prioritizes GSK's Breakthrough Drug Jemperli for Endometrial Cancer Treatment, a First in Decades
June 06, 2023
Via
Benzinga
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
June 01, 2023
From
GSK plc
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 25, 2023
Via
Benzinga
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
May 19, 2023
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the
Via
Benzinga
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
May 16, 2023
RSV is a key part of Moderna's respiratory vaccine business.
Via
The Motley Fool
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
May 15, 2023
The U.S.
Via
Benzinga
3 Personalized Medicine Stocks to Buy for Long-Time Returns
May 15, 2023
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.
Via
InvestorPlace
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
May 12, 2023
GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm
Via
Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
May 12, 2023
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have
Via
Benzinga
GSK Trims Stake On Consumer Business Spin Off, Raises £804M
May 12, 2023
GSK Plc (NYSE: GSK) sold 240 mi
Via
Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
May 12, 2023
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies.
Via
Investor's Business Daily
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
May 11, 2023
RSV could be the next big battleground for big pharma -- but it could soon become crowded.
Via
The Motley Fool
Dividend Income Update April 2023
May 11, 2023
With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated.
Via
Talk Markets
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
May 08, 2023
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
Via
MarketBeat
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
May 08, 2023
The World Health Organization ended the global emergency
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.